Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
Research output: Contribution to journal › Article › peer-review
4Scopus
citations
Fingerprint
Dive into the research topics of 'Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma'. Together they form a unique fingerprint.